Posluma Approved for PET Imaging in Prostate Cancer

Flotufolastat fluorine-18 (Posluma), a new PSMA-targeted PET radiopharmaceutical, has been approved in the US for use in prostate cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/992577?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost